Syros Pharmaceuticals, Inc. is not engaged in any business activities. The Company is actively engaged in the voluntary delisting process. The Company was previously engaged in developing new standards of care for the frontline treatment of patients with hematologic malignancies.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-06-26	US$0.000100	0.00%	1,072
26-06-25	US$0.000100	0.00%	2,802
26-06-24	US$0.000100	0.00%	17,053
26-06-23	US$0.000100	0.00%	1,118
26-06-22	US$0.000100	0.00%	20,376

Delayed Quote OTC Markets

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - OTC Markets Other stock markets 15:14:52 2026-06-26 EDT			5-day change	1st Jan Change
0.000100 ^USD	0.00%		0.00%	-75.00%

25-03-23	Syros Pharmaceuticals, Inc.(OTCPK:SYRS) dropped from S&P TMI Index	CI
25-03-18	Syros Pharmaceuticals, Inc.(OTCPK:SYRS) dropped from NASDAQ Composite Index	CI

Market Cap	6.17M 5.41M 4.98M 4.67M 8.75M 582M 8.93M 59.9M 23.18M 287M 23.15M 22.65M 997M	P/E 2022	-0.48x	P/E 2023	-1.34x
Enterprise Value	-71.28M -62.5M -57.61M -53.94M -101M -6.72B -103M -692M -268M -3.32B -268M -262M -11.52B	EV / Sales 2022	-4.44x	EV / Sales 2023	12.6x
Free-Float	99.85%	Yield 2022 *	-	Yield 2023	-

25-03-23	Syros Pharmaceuticals, Inc.(OTCPK:SYRS) dropped from S&P TMI Index	CI
25-03-18	Syros Pharmaceuticals, Inc.(OTCPK:SYRS) dropped from NASDAQ Composite Index	CI
25-02-28	Syros Pharmaceuticals to Delist from Nasdaq, Deregister Common Shares	MT
25-02-28	Syros Pharmaceuticals, Inc. Announces Cessation of Gerald Quirk as Chief Executive Officer, Effective March 01, 2025	CI
25-02-28	Syros Pharmaceuticals, Inc. Announces Management Changes	CI
24-12-22	Syros Pharmaceuticals, Inc.(NasdaqGS:SYRS) dropped from S&P Global BMI Index	CI
24-11-13	Brookline Capital Downgrades Syros Pharmaceuticals to Hold	MT
24-11-13	TD Cowen Downgrades Syros Pharmaceuticals to Hold	MT
24-11-13	JMP Securities Downgrades Syros Pharmaceuticals to Market Perform	MT
24-11-13	HC Wainwright Downgrades Syros Pharmaceuticals to Neutral, $1 Price Target	MT
24-11-13	Syros Pharmaceuticals, Inc. Announces Event of Default Occurred Under the Loan and Security Agreement with Oxford Finance LLC	CI
24-11-12	Syros Pharmaceuticals Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression	CI
24-10-31	Syros Pharmaceuticals, Inc., Q3 2024 Earnings Call, Oct 31, 2024

24-11-13	Brookline Capital Downgrades Syros Pharmaceuticals to Hold	MT
24-11-13	TD Cowen Downgrades Syros Pharmaceuticals to Hold	MT
24-11-13	JMP Securities Downgrades Syros Pharmaceuticals to Market Perform	MT
24-11-13	HC Wainwright Downgrades Syros Pharmaceuticals to Neutral, $1 Price Target	MT
23-05-11	JMP Securities Adjusts Price Target on Syros Pharmaceuticals to $15 From $16, Maintains Market Outperform Rating	MT

Syros Pharmaceuticals, Inc. Stock

Stocks

SYRS

US87184Q2066

Biotechnology & Medical Research

Valuation: Syros Pharmaceuticals, Inc.

Chart: Syros Pharmaceuticals, Inc.

Latest news : Syros Pharmaceuticals, Inc.

Analysts' recommendations: Syros Pharmaceuticals, Inc.

Press Releases: Syros Pharmaceuticals, Inc.

News in other languages: Syros Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Syros Pharmaceuticals, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

25-02-28	Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration	BU
24-11-18	Syros Pharmaceuticals : Management Change/Compensation Form 8 K	PU
24-11-13	Syros Pharmaceuticals : Announces Topline Data from SELECT MDS 1 Phase 3 Trial of Tamibarotene in Higher Risk Myelodysplastic Syndrome with RARA Gene Overexpression Form 8 K	PU
24-11-12	Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression	BU
24-11-01	Syros Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides a Business Update	AQ

23-07-24	USA-Les valeurs à suivre à Wall Street (actualisé)
21-08-05	Bourse Zurich: le SMI termine dans le vert juste sous les 12'200 points
21-08-05	Roche signe un accord de livraison avec Syros Pharmaceuticals

Current month	-50.00%
1 month	-50.00%
3 months	-75.00%
6 months	-87.50%
Current year	-75.00%

1 week	0		0
1 month	0		0
Current year	0		0.01
1 year	0		0.04
3 years	0		8.17
5 years	0		57.3
10 years	0		243.75

Manager	Title	Age	Since
Gerald Quirk CEO	Chief Executive Officer	58	2024-11-21
Karen Hunady IRC	Investor Relations Contact	-	2022-09-30
Matthew Foster PRN	Corporate Officer/Principal	-	2025-02-28

Date	Insider	Type	Main position	Quantity	% Market Cap.
24-12-01	Nancy Simonian	Sell	Chief Executive Officer	37,070	0.1382%
24-11-24	Nancy Simonian	Sell	Chief Executive Officer	134,713	0.5025%
24-11-18	Gerald Quirk	Sell	Chief Financial Officer	46,657	0.1740%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SYROS PHARMACEUTICALS, INC.	0.00%	0.00%	-99.66%	-100.00%	2.68K
LONZA GROUP AG	-0.48%	+7.20%	-5.08%	+2.45%	46.36B
REVOLUTION MEDICINES, INC.	+2.19%	+11.71%	+385.81%	+632.13%	37.88B
IQVIA HOLDINGS INC.	+2.53%	+13.93%	+20.85%	-10.61%	31.12B
BEONE MEDICINES AG	+1.65%	+3.61%	+9.98%	+55.42%	30.61B
CELLTRION, INC.	-4.16%	-2.58%	+8.74%	+15.22%	24.69B
ASCENDIS PHARMA A/S	-0.32%	+12.96%	-	-	16.25B
MEDPACE HOLDINGS, INC.	+1.37%	+14.53%	+71.80%	+134.14%	14.85B
EUROFINS SCIENTIFIC SE	+1.00%	+10.30%	+13.31%	+22.84%	13.58B
IONIS PHARMACEUTICALS, INC.	+3.63%	+9.53%	+104.07%	+107.62%	12.95B
Average	+0.74%	+8.31%	+56.65%	+95.47%	22.83B
Weighted average by Cap.	+0.71%	+8.99%	+85.56%	+139.10%

	2022	2023
Net sales	14.88M 13.05M 12.03M 11.26M 21.11M 1.4B 21.55M 145M 55.93M 694M 55.87M 54.65M 2.41B	9.94M 8.71M 8.03M 7.52M 14.1M 937M 14.39M 96.52M 37.35M 463M 37.31M 36.49M 1.61B
Net income	-94.65M -82.99M -76.5M -71.62M -134M -8.93B -137M -919M -356M -4.41B -355M -348M -15.3B	-165M -144M -133M -125M -234M -15.52B -238M -1.6B -619M -7.67B -618M -604M -26.61B
Net Debt	-139M -122M -112M -105M -197M -13.09B -201M -1.35B -521M -6.47B -521M -510M -22.43B	-77.45M -67.91M -62.6M -58.6M -110M -7.31B -112M -752M -291M -3.61B -291M -284M -12.52B